MedTrace Logo

Understanding the Paradoxical Rise in Blood Glucose in the Context of a Low-carbohydrate Diet

NCT07713316 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-20

No results posted yet for this study

Summary

The purpose of this project was to elucidate the phenomenon of elevated blood glucose in the context of dietary carbohydrate restriction. Accordingly, we sought to quantify glucagon, and related hormones, between individuals that are adhering to a low-carbohydrate diet that manifests with normal vs. elevated glucose. Moreover, we sought to test the dynamic effect of macronutrients on these same outcomes. Each participant completed 3 testing periods that included the consumption of a glucose drink, protein drink, or fat (olive oil) drink in a random order and separated by at least 2 days. Each drink was matched for volume and total calories and bloodwork was taken every 30 minutes to assess the outcomes of interest.

Conditions

  • Elevated Blood Glucose
  • Low-carbohydrate Diet

Interventions

DIETARY_SUPPLEMENT

Carbohydrate Drink

300 kcal of dextrose mixed in water.

DIETARY_SUPPLEMENT

Fat Drink

300 kcal of olive oil mixed in water.

DIETARY_SUPPLEMENT

Protein Drink

300 kcal of whey protein in water.

Sponsors & Collaborators

  • Levels Health Inc.

    collaborator OTHER

  • Brigham Young University

    lead OTHER

Principal Investigators

  • Benjamin Bikman, PhD · Brigham Young University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2022-06-30
Completion
2022-12-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713316 on ClinicalTrials.gov